Clinical Trial

A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania

Study acronym: PROGRESS-RO
Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to assess the proportion of participants with moderate-to-severe plaque psoriasis who continue treatment with guselkumab over a two-year period.
Protocol Amendment History 3 changes
notable Trial sites expanded: 6 -> 19 locations 2026-07-07
critical Recruitment opened 2026-06-13
notable Trial sites expanded: 0 -> 6 locations 2026-06-13
Trial Details
NCT Number NCT07582783
Lead Sponsor Janssen Research & Development, LLC
Conditions Psoriasis
Enrollment 200 participants
Start Date 2026-05-15
Primary Completion 2028-09-15 (estimated)
Study Completion 2028-11-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-06